Search Results - "Sivcheva, Liliya"

Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials by Bussel, James, Arnold, Donald M., Grossbard, Elliot, Mayer, Jiří, Treliński, Jacek, Homenda, Wojciech, Hellmann, Andrzej, Windyga, Jerzy, Sivcheva, Liliya, Khalafallah, Alhossain A., Zaja, Francesco, Cooper, Nichola, Markovtsov, Vadim, Zayed, Hany, Duliege, Anne‐Marie

“…Spleen tyrosine kinase (Syk) signaling is central to phagocytosis‐based, antibody‐mediated platelet destruction in adults with immune thrombocytopenia (ITP)…”
Get full text

S145: VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY by Al‐Sawaf, Othman, Robrecht, Sandra, Zhang, Can, Olivieri, Stefano, Chang, Yi Meng, Fink, Anna‐Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Kreuzer, Karl‐Anton, Sivcheva, Liliya, Niemann, Carsten, Schwarer, Anthony, Loscertales Pueyo, Javier, Weinkove, Robert, Strumberg, Dirk, Kilfoyle, Allanah, Runkel, Eva, Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael, Fischer, Kirsten

Get full text

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial by Al-Sawaf, Othman, Zhang, Can, Tandon, Maneesh, Sinha, Arijit, Fink, Anna-Maria, Robrecht, Sandra, Samoylova, Olga, Liberati, Anna M, Pinilla-Ibarz, Javier, Opat, Stephen, Sivcheva, Liliya, Le Dû, Katell, Fogliatto, Laura M, Niemann, Carsten U, Weinkove, Robert, Robinson, Sue, Kipps, Thomas J, Tausch, Eugen, Schary, William, Ritgen, Matthias, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Eichhorst, Barbara, Stilgenbauer, Stephan, Hallek, Michael, Fischer, Kirsten

“…Venetoclax plus obinutuzumab has been established as a fixed-duration treatment regimen for patients with chronic lymphocytic leukaemia. We compared the…”
Get full text

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions by Fischer, Kirsten, Al-Sawaf, Othman, Bahlo, Jasmin, Fink, Anna-Maria, Tandon, Maneesh, Dixon, Mark, Robrecht, Sandra, Warburton, Simon, Humphrey, Kathryn, Samoylova, Olga, Liberati, Anna M, Pinilla-Ibarz, Javier, Opat, Stephen, Sivcheva, Liliya, Le Dû, Katell, Fogliatto, Laura M, Niemann, Carsten U, Weinkove, Robert, Robinson, Sue, Kipps, Thomas J, Boettcher, Sebastian, Tausch, Eugen, Humerickhouse, Rod, Eichhorst, Barbara, Wendtner, Clemens-Martin, Langerak, Anton W, Kreuzer, Karl-Anton, Ritgen, Matthias, Goede, Valentin, Stilgenbauer, Stephan, Mobasher, Mehrdad, Hallek, Michael

“…The combination of the BCL2 inhibitor venetoclax plus obinutuzumab was more effective in the treatment of older medically ill patients with untreated chronic…”
Get full text

Individualized Dosing of Ropeginterferon Alfa-2b Ensures Optimal Response in Patients with Low-Risk Polycythemia Vera (PV) by Gisslinger, Heinz, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Liliya, Mayer, Jiri, Yablokova, Vera, Krejcy, Kurt, Empson, Victoria, Hasselbalch, Hans, Kralovics, Robert, Kiladjian, Jean-Jacques

“…Introduction: Ropeginterferon alfa-2b at a fixed dose of 100 µg/2 weeks was efficacious in patients with low-risk polycythemia vera (PV) in the Low-PV trial,…”
Get full text

Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group by Simon, Florian, Ligtvoet, Rudy, Robrecht, Sandra, Cramer, Paula, Kutsch, Nadine, Furstenau, Moritz, Goede, Valentin, Von Tresckow, Julia, Langerbeins, Petra, Fink, Anna-Maria, Huber, Henriette, Tausch, Eugen, Schneider, Christof, Wendtner, Clemens-Martin, Ritgen, Matthias, Dreyling, Martin, Müller, Lothar, Jacobasch, Lutz, Heinz, Werner, Vehling-Kaiser, Ursula, Sivcheva, Liliya, Böttcher, Sebastian, Dreger, Peter, Illmer, Thomas, Gregor, Michael, Staber, Philipp Bernhard, Stilgenbauer, Stephan, Niemann, Carsten Utoft, Kater, Arnon P., Fischer, Kirsten, Eichhorst, Barbara F., Hallek, Michael, Al-Sawaf, Othman

“…Introduction Overall survival (OS) is generally considered the most patient-relevant endpoint in oncology trials, however, its implementation can entail…”
Get full text

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia by Al-Sawaf, Othman, Fürstenau, Moritz, Giza, Adam, Robrecht, Sandra, Von Tresckow, Julia, Fink, Anna Maria, Simon, Florian, Tausch, Eugen, Schneider, Christof, Sivcheva, Liliya, Schwarer, Anthony, Loscertales, Javier, Weinkove, Robert, Strumberg, Dirk, Kilfoyle, Allanah R., Juliusson, Gunnar, Da Cunha-Bang, Caspar, Illmer, Thomas, Gregor, Michael, Thornton, Patrick, Janssens, Ann, Tadmor, Tamar, Lindström, Vesa, Staber, Philipp Bernhard, Levin, Mark-David, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Ritgen, Matthias, Stilgenbauer, Stephan, Kater, Arnon P., Niemann, Carsten Utoft, Fischer, Kirsten, Eichhorst, Barbara F., Hallek, Michael

“…Introduction Following the results of two phase-III studies, the CLL14 study, recruiting elderly and unfit patients (pts) with chronic lymphocytic leukemia…”
Get full text

End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia by Simon, Florian, Ligtvoet, Rudy, Robrecht, Sandra, Cramer, Paula, Kutsch, Nadine, Fürstenau, Moritz, Goede, Valentin, von Tresckow, Julia, Langerbeins, Petra, Fink, Anna-Maria, Huber, Henriette, Tausch, Eugen, Schneider, Christof, Wendtner, Clemens M., Ritgen, Matthias, Dreyling, Martin, Müller, Lothar, Jacobasch, Lutz, Heinz, Werner J., Vehling-Kaiser, Ursula, Sivcheva, Liliya, Böttcher, Sebastian, Dreger, Peter, Illmer, Thomas, Gregor, Michael, Staber, Philipp B., Stilgenbauer, Stephan, Niemann, Carsten U., Kater, Arnon P., Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael, Al-Sawaf, Othman

“…PURPOSE Surrogate end points are commonly used to estimate treatment efficacy in clinical studies of chronic lymphocytic leukemia (CLL). This patient- and…”
Get full text

Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study by Al-Sawaf, Othman, Robrecht, Sandra, Zhang, Can, Olivieri, Stefano, Chang, Yi Meng, Fink, Anna-Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Kreuzer, Karl-Anton, Sivcheva, Liliya, Niemann, Carsten Utoft, Schwarer, Anthony P, Loscertales, Javier, Weinkove, Robert, Strumberg, Dirk, Kilfoyle, Allanah, Manzoor, Beenish S, Jawaid, Dureshahwar, Emechebe, Nnadozie, Devine, Jacob, Boyer, Michelle, Runkel, Eva D, Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael J, Fischer, Kirsten

“…Venetoclax-obinutuzumab (Ven-Obi) is a standard-of-care for patients with previously untreated chronic lymphocytic leukemia (CLL). In the CLL14 study, patients…”
Get full text

Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients by Gisslinger, Heinz, Klade, Christoph, Georgiev, Pencho, Skotnicki, Aleksander, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Rossiev, Viktor, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Liliya, Mayer, Jiri, Grohmann-Izay, Barbara, Hasselbalch, Hans, Kralovics, Robert, Kiladjian, Jean-Jacques

“…▪ Background: Interferon alfa (IFNa) based therapies have been successfully applied in myeloproliferative neoplasms (MPN) for over thirty years. Several…”
Get full text

Endpoint Surrogacy in First-Line Chronic Lymphocytic Leukemia by Simon, Florian, Ligtvoet, Rudy, Robrecht, Sandra, Cramer, Paula, Kutsch, Nadine, Fürstenau, Moritz, Goede, Valentin, von Tresckow, Julia, Langerbeins, Petra, Fink, Anna-Maria, Huber, Henriette, Tausch, Eugen, Schneider, Christof, Wendtner, Clemens M, Ritgen, Matthias, Dreyling, Martin, Müller, Lothar, Jacobasch, Lutz, Heinz, Werner J, Vehling-Kaiser, Ursula, Sivcheva, Liliya, Böttcher, Sebastian, Dreger, Peter, Illmer, Thomas, Gregor, Michael, Staber, Philipp B, Stilgenbauer, Stephan, Niemann, Carsten U, Kater, Arnon P, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael, Al-Sawaf, Othman

“…Surrogate endpoints are commonly used to estimate treatment efficacy in clinical studies of chronic lymphocytic leukemia (CLL). This patient- and trial-level…”
Get full text